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AbstrACt
Objectives To explore treatment behaviours in a cohort 
of Italian patients with hereditary angioedema due to 
complement C1-inhibitor deficiency (C1-INH-HAE), and 
to estimate how effects and costs of treating attacks in 
routine practice differed across available on-demand 
treatments.
Design Cost analyses and survival analyses using attack-
level data collected prospectively for 1 year.
setting National reference centre for C1-INH-HAE.
Participants 167 patients with proved diagnosis of 
C1-INH-HAE, who reported data on angioedema attacks, 
including severity, localisation and duration, treatment 
received, and use of other healthcare services.
Interventions Attacks were treated with either icatibant, 
plasma-derived C1-INH (pdC1-INH) or just supportive care.
Main outcome measures Treatment efficacy in reducing 
attack duration and the direct costs of acute attacks.
results Overall, 133 of 167 patients (79.6%) reported 
1508 attacks during the study period, with mean 
incidence of 11 attacks per patient per year. Only 78.9% 
of attacks were treated in contrast to current guidelines. 
Both icatibant and pdC1-INH significantly reduced attack 
duration compared with no treatment (median times from 
onset 7, 10 and 47 hours, respectively), but remission 
rates with icatibant were 31% faster compared with pdC1-
INH (HR 1.31, 95% CI 1.14 to 1.51). However, observed 
treatment behaviours suggest patterns of suboptimal 
dosing for pdC1-INH. The average cost per attack was 
€1183 (SD €789) resulting in €1.58 million healthcare 
costs during the observation period (€11 912 per patient 
per year). Icatibant was 54% more expensive than pdC1-
INH, whereas age, sex and prophylactic treatment were 
not associated to higher or lower costs.
Conclusions Both icatibant and pdC1-INH significantly 
reduced attack duration compared with no treatment, 
however, icatibant was more effective but also more 
expensive. Treatment behaviours and suboptimal dosing 
of pdC1-INH may account for the differences, but further 
research is needed to define their role.
IntrODuCtIOn 
Hereditary angioedema is most commonly due 
to genetic complement C1-inhibitor deficiency 
(C1-INH-HAE). Its prevalence is uncertain, 
with estimates ranging between 1 in 10 000 
and 1 in 150 000 persons1–4 worldwide, whereas 
in Italy, minimum calculated prevalence was 
found to be 1:64 000.5 C1-INH-HAE is char-
acterised by periodic self-limiting oedema 
of the extremities, face, genitals, gastroin-
testinal and upper airway mucosa. All symp-
toms can cause temporary disability and are 
life-threatening because of asphyxiation when 
located at the larynx. Their pathophysiology 
is well defined6: C1-INH controls the activity 
of contact system enzymes, factor XIIa and 
plasma kallikrein. C1-INH deficiency facilitates 
contact system activation and local release of 
the vasoactive peptide bradykinin, responsible 
for oedema formation.7 Frequency and severity 
of angioedema recurrences are highly vari-
able and represent the main drivers of disease 
burden. In fact, due to the invalidating nature 
strengths and limitations of this study
 ► This study exploits data on 1508 hereditary an-
gioedema attacks, prospectively collected over 
1 year from 133 patients, out of a total sample of 
167 patients.
 ► A number of statistical models have been explored 
to account for different assumptions in the data 
structure.
 ► In the absence of direct evidence from clinical stud-
ies, this study uses real-world data to estimate the 
relative effectiveness of plasma-derived C1-inhibitor 
and icatibant.
 ► Limitations of this study include that, since treatment 
for acute attacks was mostly self-administered at 
home, there is no way to control for patients seek-
ing treatments inappropriately or in the absence of a 
true hereditary angioedema attack.
 ► The data did not include information on weight, and 
other patients characteristics, limiting the interpre-
tation of the observed treatment patterns and the 
role of these characteristics on treatment costs and 
outcomes.
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of attacks, individuals with C1-INH-HAE suffer from severe 
deterioration in their quality of life. In addition, at the 
societal level, C1-INH-HAE causes substantial productivity 
losses due to missed time at school or work for patients 
and their caregivers, as well as long-term consequences 
for education attainment and careers.8–10 Therapies for 
on-demand treatment (ODT) of C1-INH-HAE attacks are 
available,11–17 and existing clinical guidelines recommend 
patients to treat all attacks at onset.18 ODTs reduce the 
time a patient has angioedema and the risk of death for 
life-threatening attacks.19 In Italy, two plasma derived and 
one recombinant C1-INH (Berinert, Cinryze, Ruconest), 
and the bradykinin receptor antagonist icatibant (Firazyr) 
are registered for ODT. However, Ruconest is not reim-
bursed by the Italian National Healthcare System, and its 
use remains marginal. Icatibant is delivered as prefilled 
syringe to be administered at a fixed dose of 30 mg, whereas 
plasma-derived C1-INH (pdC1-INH) is delivered in vials 
of 500 IU for a weight-based dose of 20 IU/Kg. The costs 
of ODTs are considerable ranging from €560 for 1 phial 
of pdC1-INH to €1695 for icatibant. Patients who do not 
reach adequate disease control on ODT can be switched to 
long-term prophylaxis (LTP),18 with attenuated androgens 
or two times per week infusions of Cinryze.17 20 Attenuated 
androgens have minimal cost, but side effects limit their 
use21 whereas the yearly cost for Cinryze prophylaxis in Italy 
is about € 150 000 per patient, and can be prescribed only 
to patients requiring four or more ODTs per month.22 
Availability of treatments for C1-INH-HAE have played 
a fundamental role in reducing the health and soci-
etal burden of the disease23; however, their high cost 
has raised several concerns among healthcare payers 
worldwide.10 24 25 Indeed, budget constrained healthcare 
systems are increasingly concerned about demonstrating 
the value for money of new treatments as a must-have 
condition for coverage and reimbursement decisions.
However, to date there is still little knowledge on a 
number aspects that are relevant to make informed deci-
sions for C1-INH-HAE treatments. These include (1) the 
average number of angioedema recurrences in patients 
with C1-INH-HAE, (2) treatment behaviours during 
attacks and (3) the relative effectiveness of available ODTs 
and their related costs. This study aims to fill this gap 
by analysing a population of patients with C1-INH-HAE 
in their real life followed prospectively for 1 year at the 
Milan angioedema centre in Italy.
MAterIAl AnD MethODs
Patients
This is a prospective observational study conducted 
at Milan angioedema centre between 1  January and 
31 December 2014. We evaluated 167 patients with 
C1-INH-HAE, who accurately recorded angioedema 
symptoms in diaries of attacks, which were subsequently 
validated by physicians. Diagnosis was based on family 
and/or personal history of recurrent angioedema, and 
on laboratory levels of C1-INH <50% of normal.
According to guidelines, all patients had ODT available 
at home and were recommended to use the treatment at 
onset of angioedema attacks.18 Treatments with Cinryze 
and Ruconest cover less than 5% of the total ODTs in Italy 
and were not considered for the study.
The following data about angioedema attacks were 
recorded in a dedicated diary by patients every time that 
they experienced an attack: (1) time of onset of symp-
toms (defined as the time when patients recognise the 
presence of an angioedema); (2) time of complete reso-
lution (defined as the time when patients recognise that 
angioedema is not present any more); (3) attack loca-
tion (peripheral, abdominal, facial, laryngeal); (4) attack 
severity, defined as impairment on daily activities (mild 
for no impairment, moderate for partial impairment and 
severe for complete impairment); (5) medication(s) and 
dose(s) used for treating the attack, and time of adminis-
tration; and (6) need for other medical assistance, diag-
nostic tests or emergency department visits.
No data were recorded that allowed to quantify produc-
tivity losses at the societal level such as days missed at work 
or school.
statistical analysis
Patients and attacks characteristics
Patients’ characteristics for the whole sample were 
summarised by reporting mean and median values for 
continuous data and frequencies (percentages) for cate-
gorical data. Attack data were reported for the whole 
sample and grouped by first-line treatment; χ2 tests with 
a significance level at p<0.05 were applied to check for 
differences in the characteristics of attacks between ODTs.
Treatment effectiveness
Two different times to attack resolution were considered, 
starting from either the onset of symptoms or the time of 
administration of the first-line ODT. While the first one 
provides a measure of the relative effectiveness between 
treatment alternatives, the second allows for comparisons 
with attacks not being treated. This second time span also 
implicitly includes potential differences in the time to 
treatment between ODT drugs that may originate from 
the different routes of administration.
Standard Kaplan-Meier26 estimates were used to esti-
mate the mean and median times to resolution. Attack 
data were required to have complete information on the 
time (date and hour) of symptoms onset, the time of treat-
ment administration and at least the day when the attack 
was reported as resolved. If the hour of the attack reso-
lution was missing, the attack was considered censored 
at the latest time between the date of treatment adminis-
tration and 00:00 hours of the reported day of resolution. 
Comparisons between treatments alternatives have been 
evaluated using log-rank test statistics, adjusted for attack 
site and attack severity. In addition, Cox proportional 
hazard models were fitted to estimate the contribution of 
a set of variables to the rate of attack resolution. The vari-
ables to be included in the model have been chosen using 
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a step function to find the model specification with the 
lowest Akaike information criterion.27 The proportional 
hazard assumption has been investigated by calculating 
Pearson product-moment correlations and by visual 
inspection of residuals plotted against attack time.
Cost analysis
For the cost analysis of C1-INH-HAE attack, the perspec-
tive of the Italian National Health Service was taken. 
Consumption of resources in the database was identified 
through ICD-9-CM codes and linked to national tariffs 
for ambulatory services28 as detailed in table 1. Drug costs 
have been estimated from official national reimburse-
ment prices that represent the maximum price to which 
local hospitals can purchase treatment drugs.29 30
Since not all patients registering an attack sought treat-
ment, the cost data present a non-negative mass at 0 costs. To 
account for this, two-part models were used, which analyse 
the data in two separate steps. First, a logistic regression 
on all data was used to estimate the probability of seeking 
treatment, adjusted for patients’ sex and age, attack site and 
attack severity; subsequently, a conditional regression was 
performed on attack data with positive cost values, evalu-
ating the contribution of each predictor on the total attack 
cost. In this second step, we adjusted for patients age and 
sex, attack site and severity, ODT drug, and time from onset 
of symptoms to treatment.
Eight different models were fitted using both frequen-
tist and Bayesian approaches. First, to account for the 
typical skewness of cost data, the second part of the model 
was parametrised using either a log-normal or a gamma 
distribution.31 Second, since each patient recorded 
multiple attacks during the observation period, different 
assumptions on the structure of the data were made, by 
considering either a multilevel structure, accounting 
for within-patient correlations or a complete pooling of 
data.32 In the first case, two distinct random effects for 
the intercept were estimated for each part of the model.
For Bayesian models, an initial run of 75 000 itera-
tions was considered as ‘burn in’ (these values were 
discarded). Two independent chains, starting from 
randomly assigned values were run, and convergence was 
monitored by looking at the ratio of the within-chain to 
between-chain variance to be about one, and by using 
Heidelberger-Welch33 and Gelman-Rubin34 diagnostics.
Following the approach proposed by Cooper et al,35 
retransformation of coefficients in the log-normal models 
was performed applying a non-parametric retransfor-
mation factor known as a ‘smearing’ estimator,36 that 
avoids efficiency and consistency problems related to the 
non-normality of the error distribution.
To assess the predictive ability of each model, data were 
randomly split into a learning sample (90% of observa-
tions), which was used to fit the models, and a test sample 
(10% of observations), which was used for model vali-
dation. The predictive ability of each model was then 
assessed using the root mean square error (RMSE) crite-
rion for the mean.
All analyses were performed using RStudio (V.3.4.0) 
and OpenBUGS (V.3.2.3).
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for the implementation of the study. No 
patients were asked to advise on interpretation or writing 
up of results. The results will be disseminated during the 
annual meeting of patients of the Italian Angioedema 
Association and on the dedicated website.
results
Descriptive results of the patients reporting attacks in the 
study period
Table 2 reports the patient-level characteristics of the 
sample.
Of all 167 patients included in the study, 34 (20%) 
reported no attacks, whereas the remaining 133 registered 
1508 angioedema attacks during the observation period. 
However, a high variability was found across patients, 
ranging from 1 to 126 attacks (IQR 14). Patients on LTP 
Table 1 Tariffs and sources for cost data
Resource use
Total 
tariff (€)
ICD-9-CM codes and 
other sources
Ambulatory visits 16.79 89.01.2
Blood and urine tests 49.28 91.49.2; 90.62.2; 90.27.1; 
90.04.5; 90.09.2; 90.10.4; 
90.43.2; 90.14.3; 90.29.2; 
90.23.5; 90.40.4; 90.37.4; 
90.11.4; 90.15.4; 90.16.3; 
90.72.3; 90.42.1; 90.38.4; 
89.66; 90.44.3
Diagnostic tests
  ECG 11.62 89.52
  Rx abdomen 19.37 88.19
  Superior abdomen 
ultrasound
60.43 88.76.1
  Total abdomen 
ultrasound
43.90 88.74.1
  MRI abdomen 187.13 89.95.2
Emergency department 
visit
109.38 €23 assumed for 
emergency acceptance 
visit+codes:
99.22; 91.49.2; 90.62.2; 
90.27.1; 90.04.5; 90.10.4; 
90.29.2; 90.40.4; 90.37.4; 
90.15.4; 90.10.2; 90.16.3; 
90.72.3; 89.52; 88.19; 
88.76.1; 89.66
Treatment
  C1-inhibitor (500 
unit)
560 Ex-factory national 
reimbursement price
  Icatibant (30 mg) 1695 Ex-factory national 
reimbursement price
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accounted for 25% of all reported attacks. Overall, the 
distributions of attack frequencies were similar in patients 
with and without LTP (figure 1A,B, respectively). Particu-
larly, the proportion of patients with ≤10 attacks was 68.8% 
for patients not on prophylaxis and 69.0% for patients on 
prophylaxis (69.1% in the whole sample). No additional 
data on LTPs were available for patients who reported no 
attacks during the observation period.
Table 3 summarises the characteristics of attacks and 
their related treatments. Attacks were more often periph-
eral (47.6%), followed by abdominal attacks (39.4%), 
facial attacks (6.2%) and laryngeal attacks (4.8%). Of 
the total number of attacks, 1190 (78.9%) were treated 
with ODT, of which 704 with pdC1-INH (59.2% of treated 
attacks) and 486 with icatibant.
treatments effectiveness
When using pdC1-INH, 30% and 40% of attacks were 
treated with a dosage considered appropriate for a weight 
of 25 and 50 kg, respectively (500 or 1000 IU). In addi-
tion, despite the recommended weight-based dosage, 
a certain amount of variability was observed within the 
same patients across attacks (online supplementary file 
1). Lastly, for 318 (21%) attacks, patients received no 
treatment or just supportive care.
Forty-four attacks (2.9%) required a second treatment, 
and this proportion was found to be higher if the first-
line treatment was icatibant compared with pdC1-INH 
(5.6% and 2.4%, respectively). Lastly, 131 attacks (8.7%) 
were treated in the emergency department, with all 
patients discharged within 4 hours. Laryngeal, abdom-
inal and facial attacks were more frequently treated with 
pdC1-INH compared with icatibant (p<0.05).
Compared with no treatment, both icatibant and 
pdC1-INH significantly reduced overall attack times 
from onset to complete resolution of symptoms (χ2 164, 
p<0.001) (table 4, figure 2A). However, icatibant showed 
faster resolution times from treatment administration, 
compared with pdC1-INH (χ2 10.6, p=0.001) (table 4, 
figure 2B).
Table 2 General characteristic of patients reporting attacks
Patients reporting angioedema attacks 
(n=133) Statistics
Age (years), mean (SD) 43 (16.9)
Female patients, n (%) 85 (64)
C1-inhibitor deficiency-hereditary angioedema 
type I, n (%)
126 (95)
Patients on long-term prophylaxis*, n (%) 29 (22)
  Danazol 15
  Stanozolol 11
  Tranexamic acid 3
No of attacks per patient per year, mean (SD) 11 (16)
No of attacks per patient per year, median (IQR) 22 (14)
Frequency of attacks per year, no of patients (%)
  1 21 (15.8)
  2–5 41 (30.8)
  6–10 30 (22.5)
  11–20 19 (14.3)
  21–30 9 (6.8)
  >30 13 (9.8)
*The number includes two patients who reported being on long-
term prophylaxis just for 3 and 4 months from their first attack.
Figure 1 Distribution of attacks per year in the C1-IHN-HAE population with (A) and without (B) long-term prophylaxis.  C1-
IHN- HAE,  C1-inhibitor deficiency- hereditary angioedema. 
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The Cox proportional hazard model estimated that remis-
sion rates when using icatibant were 31% faster compared 
with pdC1-INH (HR 1.31, 95% CI 1.14 to 1.51) (table 5). 
Attack severity and attack site were not found to be asso-
ciated with different remission rates, with the only excep-
tion for laryngeal attacks (HR 1.44, 95% CI 1.07 to 1.95). 
In addition, shorter time to treatment was associated with 
a small (2%) but significant positive effect on remission 
rates (HR 0.98, 95% CI 0.97 to 0.99), suggesting that each 
additional hour between onset of symptoms and treatment 
administration would increase the chance of a faster reso-
lution by approximately 2%. Lastly, when comparing attack 
duration with icatibant and pdC1-INH versus no treatment, 
remission rates were found to be 2.5 times and 3 times 
higher (HR 3.16, 95% CI 2.62 to 3.80; and HR 2.45, 95% CI 
2.05 to 2.93, respectively) (table 5).
Cost analysis
Total costs during the observation period amounted to 
€1.58 million, equivalent to slightly more than €11 900 
per patient per year. The average cost for a single attack 
cost was €1183 (SD €789) including drug costs, emer-
gency department visits and diagnostic tests.
The complete results of all cost models are reported in 
the online supplementary file 2. The model with the best 
predictive ability, based on RMSE, was a multilevel model 
with the second regression parameterised as a gamma 
distribution with a log link (RMSE=389.02).
Patients’ sex, age and whether they were on LTP did 
not significantly influence the cost and were taken out of 
the model to improve predictive ability and fit.
Drug type was the most relevant cost driver. The unad-
justed mean cost per attack was €1069 (SD €470) with 
pdC1-INH and €1651 (SD €469) with icatibant. After 
controlling for attack site and severity, the cost of treating 
Table 3 Characteristics of attacks (all attacks and by treatment received)
Total attacks n=1508 pdC1-INH n=704 Icatibant n=486 No treatment n=318
Location
  Throat larynx (%) 72 (4.8) 50 (7.1)*† 18 (3.7)* 4 (1.4)
  Abdominal (%) 594 (39.4) 279 (39.6)*† 236 (48.6)* 79 (24.9)
  Cutaneous peripheral (%) 718 (47.6) 287 (40.7)* 207 (42.6)* 224 (70.5)
  Face (%) 93 (6.2) 58 (8.2)*† 25 (5.1) 10 (3.2)
  Not reported (%) 31 (2.0) 31 (4.4) 0 (0) 0 (0)
Severity
  Mild (%) 360 (23.9) 146 (20.7)* 102 (21.0)* 112 (35.2)
  Moderate (%) 718 (47.6) 344 (48.9) 231 (47.6) 143 (45.0)
  Severe (%) 430 (28.5) 214 (30.4)* 153 (31.4)* 63 (19.8)
Second treatment (%) 44 (2.9) 17 (2.4)* 27 (5.6)
Prophylaxis
  No (%) 1132 (75.3) 508 (72.2)* 388 (79.8) 236 (74.2)
  Yes (%) 372 (24.7) 194 (27.8)* 96 (20.2) 82 (25.8)
Dosage for pdC1-INH
  Dose pdC1-INH 500 IU (%) 211 (30.0)
  Dose pdC1-INH 1000 IU (%) 277 (39.3)
  Dose pdC1-INH 1500 IU (%) 181 (25.7)
  Dose pdC1-INH 2000 IU (%) 27 (3.9)
  Dose not reported (%) 8 (1.2)
Emergency department admission 131 (8.7) 115 (16.3)*† 6 (1.2)* 10 (31.4)
*P<0.05, comparison versus no treatment.
†P<0.05, comparison versus icatibant.
pdC1-INH, plasma derived C1-inhibitor.
Table 4 Mean and median times to complete resolution of 
attack symptoms
Treatment
Mean time 
(SE)
Median time 
(95% CI)
 Time from treatment administration
  pdC1-INH, plasma derived 
C1-inhibitor  (pdC1-INH) 14.10 (0.88) 7.5 (7 to 8.5)
  Icatibant 11.60 (1.04) 4 (3.5 to 5)
Time from onset of symptoms
  No treatment 50.5 (2.42) 47 (42 to 54)
  pdC1-INH 18.5 (1.09) 10 (9 to 10)
  Icatibant 15.3 (1.17) 7 (6 to 8)
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an attack with icatibant was still 54% higher than pdC1-INH 
(figure 3).
Facial, laryngeal and abdominal attacks tended to 
generate higher costs than cutaneous attacks (22%, 16% 
and 11%, respectively). Severe and moderate attacks were 
30% and 17% more expensive than mild attacks. Lastly, 
the time between onset of symptoms and treatment 
administration was not found to be a significant predictor 
of higher or lower costs.
DIsCussIOn
This study analyses data from a population of 167 patients 
with C1-INH-HAE, and reports detailed information 
on 1508 attacks, including treatment behaviour, attack 
duration, received ODTs and use of other healthcare 
services. On average patients reported 11 attacks per year 
confirming the results of a previous prospective study on 
103 patients, that found an average of 10 attacks during 
the same observation period.37 The total cost per year in 
the population was €1.58 million, equivalent to slightly 
more than €11 900 per patient per year. The average 
cost for a single attack was €1183 (SD=€789), with vari-
ations mainly depending on ODT drug, attack severity 
and attack site. Particularly the cost for an attack treated 
with icatibant was found to be €1651 (SD €469), or 54% 
higher than pdC1-INH after controlling for attack site 
and severity. On the effectiveness side, this study confirms 
the efficacy of both ODTs on shortening attack dura-
tion.16 38 39 In fact, remission rates after receiving icatibant 
and pdC1-INH were found to be 2.5 times and 3 times 
faster compared with no treatment. In addition, data 
showed that icatibant improved the chance of remission 
by 31% compared with pdC1-INH (HR 1.31, 95% CI 1.14 
to 1.51). Nonetheless, a certain variability in the dosing 
of pdC1-INH was found within the same patients across 
attacks. Although patients’ weight was not available in the 
data, this result seems to support the authors’ experience 
that, despite weight-based recommended doses, patients 
treating attacks with pdC1-INH tend to self-administrate 
the minimum dose at onset (500 IU) and to take further 
vials only if the attack persists or progresses in severity.
There is a paucity of studies exploring attack frequency 
and treatment costs based on prospectively collected 
data at the attack level. A recent multicentre cluster-ran-
domised controlled study40 investigated the impact on 
resource use and quality-adjusted life years (QALYs) of 
a dedicated telephone care-management service for 
patients with C1-INH-HAE. Results showed that the 
Figure 2 Kaplan-Meier curves of attack resolution from onset of symptoms (A) and treatment administration (B). C1-INH, C1-
inhibitor. 
Table 5 Results from the Cox proportional hazard model
Time from 
treatment to attack 
resolution HR 
(95% CI)
Time from 
symptoms onset to 
attack resolution HR 
(95% CI)
Treatment
  Icatibant versus 
pdC1-INH
1.31 (1.14 to 1.51)
  pdC1-INH versus no 
treatment
2.45 (2.05 to 2.93)
  Icatibant versus no 
treatment
3.16 (2.62 to 3.80)
Time to treatment 0.98 (0.97 to 0.99)
Attack severity (vs low severity)
  Moderate 1.01 (0.84 to 1.22) 1.02 (0.87 to 1.19)
  High 0.83 (0.67 to 1.03) 0.85 (0.70 to 1.02)
Patients age (vs age 0–24 years)
  25–55 years 1.46 (1.2 to 1.77) 1.24 (1.04 to 1.48)
  >55 years 1.42 (1.1 to 1.84) 1.25 (0.98 to 1.56)
Attack site (vs cutaneous/peripheral attack)
  Abdominal 0.94 (0.81 to 1.09) 0.91 (0.79 to 1.04)
  Face 1.07 (0.79 to 1.44) 1.18 (0.89 to 1.57)
  Throat larynx 1.44 (1.07 to 1.95) 1.68 (1.25 to 2.25)
On prophylaxis 0.88 (0.75 to 1.03) 1.01 (0.89 to 1.17)
pdC1-INH, plasma derived C1-inhibitor. 
p> 0.05 is shown in bold.
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intervention significantly reduced the number of hospital 
admission in comparison with usual practice, thus leading 
to a reduction in overall hospital costs. The study also esti-
mated lower expected drug costs over 2 years ($11 874 
vs $12 496) and improvements in QALYs gained (1.42 
vs 1.40), although these latter estimates were not statisti-
cally significant. Previous studies relied on a retrospective 
surveys to infer the average cost of acute attacks during 
1 year.41 42 In Italy, estimated healthcare direct costs from 
a survey of 17 patients using pdC1-INH at home were 
found to be almost double than the results of this study 
(€26 522 per patient per year). This difference is mainly 
attributable to different costs of ODTs, that may in turn 
be justified by different estimates in the number of attacks 
(not reported in the study).
In addition, while there exist clinical studies comparing 
icatibant and pdC1-INH to placebo, no direct evidence 
was found on the relative effectiveness of available 
ODTs. Since heterogeneous study protocols and small 
study populations hamper indirect and mixed treatment 
comparisons, this study provides useful insights on the 
real-world relative effectiveness of pdC1-INH compared 
with icatibant. This study has also several limitations. 
Since treatment for acute attacks was mostly self-admin-
istered at home, there is no way to control for patients 
taking ODTs inappropriately or in the absence of a true 
C1-INH-HAE attack. In addition, although all patients 
were recommended to report attacks at occurrence, 
reporting rates may have been different across patients, 
for example, depending on severity and attack frequency. 
Consequently, it may be that the aggregated and per 
patient costs of attacks are not representative of the 
whole patient population in Italy. In addition, since the 
data did not include information on weight, the present 
study can only provide educated guesses on the potential 
patterns of undertreatment with pdC1-INH and its role 
on treatment costs and efficacy. A modified version of the 
report form has been implemented since January 2018 
and will contribute to better explain patients’ behaviours. 
A further limitation of the data used in this study is that 
no adjustments were possible for patient characteristics 
other than age and sex. Therefore, a word of caution 
is warranted in that differences in treatment costs and 
outcomes may be partially due to original imbalances 
in patients groups. Lastly, as with all registry data, recall 
bias issues may exist. Despite being a potential source of 
concern, these data still provide valuable information on 
a large sample of patients and attacks that would not have 
been feasible to obtain through other studies with more 
rigid data collection protocols.
The results of the study provide valuable insights that 
are relevant to clinicians and policy-makers. First, despite 
recommendations from clinical guidelines to treat all 
attacks at onset, 21% of the reported attacks were not 
treated with any available ODT. Second, average time 
from onset of symptoms to treatment was about 4 hours, 
and data suggest that this delay is associated with a 
small but significant negative effect on remission rates, 
confirming clinical recommendations on the need for 
early treatment. However, one of the possible reasons for 
Figure 3 Determinants of the cost of attacks. Coefficients (95% CI) from cost model. pdC1-INH, plasma derived C1-inhibitor.
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this delay is the sneaky onset of attacks that creates uncer-
tainty on symptoms’ interpretation, resulting in patients 
taking treatment when the attack severity has already 
progressed.
The observed variability in the dosing of pd-C1-INH 
largely explains the differences in costs across treatments, 
and it raises questions on whether the differential in effec-
tiveness found between pdC1-INH and icatibant is due to 
inappropriate dosage with pdC1-INH. Indeed, a previous 
meta-analysis of controlled studies using plasma-derived 
and recombinant C1-INH showed a direct correlation 
between doses and efficacy.43 Further research is needed 
to better explore potential patterns of undertreatment 
with pdC1-INH and its main determinants.
Lastly, 22% of the study population was treated with 
LTP during the observation period. Of these, almost 70% 
reported less than 10 attacks per year. Considering that in 
the study population LTP with attenuated androgens was 
prescribed only to patients with two or more attacks per 
months, these data provide further evidence in support 
to the effectiveness of LTP with attenuated androgens. 
Until 2010, attenuated androgens have been the only 
effective approach and were largely used despite signifi-
cant side effects.21 More recently, new studies supported 
the introduction of regular intravenous infusions of 
pdC1-INH (Cinryze).17 This approach massively replaced 
attenuated androgens for LTP in the USA, whereas in Italy, 
its use remains limited. Nonetheless, LTP with Cinryze is 
far more expensive than attenuated androgens44 calling 
for appropriate cost-effectiveness studies to demonstrate 
its value for money and to inform clinical guidelines. The 
results presented in this study may be used to populate 
future economic evaluations to inform decision-making 
on both prophylactic and ODTs.
COnClusIOn
The study defined the direct costs and relative effi-
cacy of ODTs in an Italian population of patients with 
C1-INH-HAE. Both icatibant and pdC1-INH signifi-
cantly reduced attack duration compared with no treat-
ment. Treatment with icatibant was more effective than 
pdC1-INH, but also significantly more expensive. Further 
research is needed to understand the role played by treat-
ment behaviours and specifically suboptimal dosing of 
pdC1-INH.
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